Cargando…
Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856751/ https://www.ncbi.nlm.nih.gov/pubmed/33530925 http://dx.doi.org/10.1186/s12882-021-02242-z |
| _version_ | 1783646307047440384 |
|---|---|
| author | Gäckler, Anja Schönermarck, Ulf Dobronravov, Vladimir La Manna, Gaetano Denker, Andrew Liu, Peng Vinogradova, Maria Yoon, Sung-Soo Praga, Manuel |
| author_facet | Gäckler, Anja Schönermarck, Ulf Dobronravov, Vladimir La Manna, Gaetano Denker, Andrew Liu, Peng Vinogradova, Maria Yoon, Sung-Soo Praga, Manuel |
| author_sort | Gäckler, Anja |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7856751 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78567512021-02-04 Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis Gäckler, Anja Schönermarck, Ulf Dobronravov, Vladimir La Manna, Gaetano Denker, Andrew Liu, Peng Vinogradova, Maria Yoon, Sung-Soo Praga, Manuel BMC Nephrol Correction BioMed Central 2021-02-02 /pmc/articles/PMC7856751/ /pubmed/33530925 http://dx.doi.org/10.1186/s12882-021-02242-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Gäckler, Anja Schönermarck, Ulf Dobronravov, Vladimir La Manna, Gaetano Denker, Andrew Liu, Peng Vinogradova, Maria Yoon, Sung-Soo Praga, Manuel Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title | Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title_full | Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title_fullStr | Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title_full_unstemmed | Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title_short | Correction to: Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| title_sort | correction to: efficacy and safety of the long-acting c5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7856751/ https://www.ncbi.nlm.nih.gov/pubmed/33530925 http://dx.doi.org/10.1186/s12882-021-02242-z |
| work_keys_str_mv | AT gackleranja correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT schonermarckulf correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT dobronravovvladimir correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT lamannagaetano correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT denkerandrew correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT liupeng correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT vinogradovamaria correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT yoonsungsoo correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis AT pragamanuel correctiontoefficacyandsafetyofthelongactingc5inhibitorravulizumabinpatientswithatypicalhemolyticuremicsyndrometriggeredbypregnancyasubgroupanalysis |